Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0893 · 3 trials · 1 indication
Blood samples were collected 30 minutes prior to all meals, and 15, 30, 60, 90, 120, 180 minutes post-meal, then and at midnight, 3 AM, and the next morning at 6:30 AM and 7:30 AM. A 24-hour weighted mean glucose (WMG) was determined by averaging multiple plasma glucose measurements over a 24-hour period.
An adverse event (AE) is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.
An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration whether or not considered related to the use of the product.
Rt(65) defined as the time to recover from hypoglycemia (blood glucose level of 50 mg/dL) to an arterialized venous blood glucose of 65 mg/dL. At t= -60 minutes on the morning of Day 1 (Visit 6) or Day 22 (Visit 8), a hypoglycemic clamp was used via an increased insulin infusion rate to achieve blood glucose concentrations of 50 mg/dL (2.8 mmol/L) within \~30-90 minutes. At the end of the 30-minute hypoglycemic clamp interval, insulin and glucose infusions were terminated, and the time to recover from hypoglycemia to 65 mg/dL Rt(65) was determined. Rt(65) was followed up to 270 minutes
| Arm | Type | Description |
|---|---|---|
| MK-0893 (40 mg) | EXPERIMENTAL | MK-0893 40-mg q.d. (quaque die, once daily) group will receive MK-0893 40-mg tablets (after loading dose with 160 mg) and matching placebo to metformin and matching placebo to MK-0893. |
| MK-0893 (120 mg) | EXPERIMENTAL | MK-0893 at 120 mg q.d. group will receive MK-0893 120 mg q.d. tablets (after loading dose of 500 mg on Day 1) and matching placebo tablets to metformin and matching placebo to MK-0893 |
| Metformin (2000 mg) | ACTIVE_COMPARATOR | Metformin taken orally, 500 mg tablets, Day 1 to Day 6: 500 mg b.i.d. (bis in die, twice daily), Day 7 to Day 13: 1000 mg in the morning and 500 mg in the evening, and Day 14 to Day 28: 1000 mg. b.i.d. and matching placebo to MK-0893. |
| Placebo | PLACEBO_COMPARATOR | Placebo tablets matching the MK-0893 and placebo tablets matching metformin. |
| Propanolol + Placebo > Propanolol + MK0893 | EXPERIMENTAL | Participants received propanolol for 7 weeks. On Day -1 of Period 1 (Study Visit 6), single dose MK0893-matched placebo was added and propanolol was continued. After Period 1, participants underwent a 3-week wash-out while continuing to receive propanolol. Following the washout, participants were treated with a single dose of MK0893 on Day 21 (Visit 8). |
| Propanolol + MK0893 > Propanolol + Placebo | PLACEBO_COMPARATOR | Participants received propanolol for 7 weeks. On Day -1 of Period 1 (Study Visit 6), single dose MK0893 was added and propanolol was continued. After Period 1, participants underwent a 3-week wash-out while continuing to receive propanolol. Following the washout, participants were treated with a single dose of MK0893-matched placebo on Day 21 (Visit 8). |
| MK-0893 40 mg→MK-0893 200 mg→placebo | EXPERIMENTAL | In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs. |
| MK-0893 200 mg→placebo→MK-0893 10 mg | EXPERIMENTAL | In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs. |
| Placebo→MK-0893 10 mg→MK-0893 40 mg | EXPERIMENTAL | In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs. |
| MK-0893 10 mg→MK-0893 40 mg→MK-0893 200 mg | EXPERIMENTAL | In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs. |
| Placebo→MK-0893 1000 mg→MK-0893 200 mg | EXPERIMENTAL | In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs. |
| MK-0893 200 mg→placebo→MK-0893 1000 mg | EXPERIMENTAL | In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs. |
| MK-0893 1000 mg→MK-0893 200 mg→placebo | EXPERIMENTAL | In Part 1 of the study, participants receive MK-0893 (10 mg, 40 mg or 200 mg) or placebo on Day 1 of each period, and Sandostatine® (30 ng/kg/min), insulin (0.10 mIU/kg/min), and glucagon (3 ng/kg/min) at 24 and 72 hours post dose. In Part 2 of the study, participants receive MK-0893 (200 mg or 1000 mg) or placebo on Day 1 of each period and Sandostatine®, insulin, and glucagon at 120 hours post dose. There will be at least 21 days between administrations of study drugs. |
| Name | Type | Description |
|---|---|---|
| MK-0893 | DRUG | 10 mg and 100 mg tablets |
| Metformin | DRUG | 500 mg metformin tablets |
| Placebo | DRUG | Placebo tablets matching MK-0893 |
| MK0893 | DRUG | Single dose of MK0893 1000 mg (ten 100 mg tablets) |
| MK0893-matched Placebo | DRUG | Single dose of placebo to MK0893 (ten tablets) |
| Propranolol Hydrochloride (HCL) | DRUG | Propranolol tablets titrated up to 80 mg three times daily over a four week period. Total treatment was approximately 7 weeks. |
| MK-0893 10 mg | DRUG | MK-0893 10 mg administered orally in 240 mL of water |
| MK-0893 40 mg | DRUG | MK-0893 40 mg administered orally in 240 mL of water |
| MK-0893 200 mg | DRUG | MK-0893 200 mg administered orally in 240 mL of water |
| MK-0893 1000 mg | DRUG | MK-0893 1000 mg administered orally in 240 mL of water |
| Sandostatine® | BIOLOGICAL | Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min. |
| Insulin | BIOLOGICAL | At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min. |
| Glucagon | BIOLOGICAL | At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min. |
Inclusion Criteria: * Type 2 diabetes * Not currently on antihyperglycemic agent (AHA) or AHA monotherapy (not to include treatment with insulin or thiazolidinediones \[i.e., peroxisome proliferator activated receptor-gamma, PPARγ agents\]) * male or a female of non-childbearing potential. Women mu...
MK-0893 is an investigational small molecule being developed for the treatment of Type 2 Diabetes Mellitus. It has been studied in clinical trials for its glucose-lowering effects, both alone and in combination with other diabetes medications. The drug is not approved and remains in clinical development.
MK-0893 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker MRK. The company has sponsored multiple clinical trials evaluating the drug's safety and efficacy in patients with Type 2 Diabetes Mellitus.
MK-0893 has completed Phase 1 and Phase 2 clinical trials. The most advanced studies are Phase 2 trials, which have been completed. The drug is investigational and has not received FDA approval. It is not currently in active clinical development according to available trial records.
MK-0893 has been studied in three completed clinical trials. These include NCT00631488, a Phase 2 study of MK-0893 in combination with other diabetes drugs; NCT00902161, a Phase 1 single-dose crossover study; and NCT02004886, a Phase 2 study assessing safety and glucose-lowering efficacy. All trials have been completed.
MK-0893 is a small molecule designed to lower blood glucose levels in patients with Type 2 Diabetes Mellitus. The specific molecular target has not been disclosed in the available clinical trial information. The drug has been evaluated for its effects on glucose metabolism in multiple clinical studies.
MK-0893 is a distinct investigational compound developed by Merck. It has been studied in combination with other diabetes medications, but it is not the same as those drugs. No alternative names for MK-0893 have been reported in the clinical trial records.